Search clinical trials for: Finerenone (Kerendia, BAY94-8862)

Total 35 results

Bayer

Recruiting

A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Chronic Kidney Disease

India
Bayer

Recruiting

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Germany, Argentina, Belgium, Brazil, Canada, Chile, Colombia, France, Italy, Korea, Republic of, Luxembourg, Mexico, Netherlands, Russian Federation, Saudi Arabia, Singapore, Slovenia, Spain, Switzerland, Taiwan, Th... and more
Bayer

Completed

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants (FIGARO-BM)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Spain, Belgium, United States, Russian Federation, Hong Kong, Singapore, Taiwan, Korea, Republic of, Canada, Austria, Italy, Japan, Denmark, Australia, Bulgaria, Czechia, Finland, Israel, Netherlands, Sweden, Portugal
Bayer

Recruiting

A Study Called SMART-Finder to Look for People With Increased Amounts of Albumin in the Urine (UACR Level) in a Group of Type 2 Diabetes Mellitus Patients (SMART-Finder)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Germany
Bayer

Recruiting

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria (FIONA)

Proteinuria | Chronic Kidney Disease

Switzerland, Belgium, Netherlands, United States, Australia, Turkey, Germany, United Kingdom, Austria, France, Hungary, Canada, Denmark, Italy, Korea, Republic of, Spain, Finland, Czechia, Sweden, Poland, Greece, Israel, China, Lithuania and more
Bayer

Recruiting

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (FIONA OLE)

Proteinuria | Chronic Kidney Disease | Children

Switzerland, Belgium, United States, Spain, Australia, United Kingdom, Argentina, Austria, Germany, Greece, Italy, France, Netherlands, Hungary, Canada, Finland, Sweden, Czechia, Poland, Turkey, Israel, Lithuania, Denmark, Korea, Republic... and more
Bayer

Active, not recruiting

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Non-diabetic Chronic Kidney Disease

Hong Kong, United States, Spain, China, Belgium, Taiwan, Australia, Korea, Republic of, Russian Federation, United Kingdom, Singapore, Malaysia, Japan, Greece, Israel, Hungary, Italy, Czechia, Denmark, Argentina, Bulgaria, Mexico, I... and more
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR) (ReFineDR)

Diabetic Retinopathy

Korea, Republic of, Russian Federation, Hong Kong, Taiwan, United States, Argentina, Japan, Denmark, Israel, Spain, Sweden, China, Colombia, Italy, Portugal
Bayer

Completed

A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Chronic Kidney Disease | Worsening Chronic Heart Failure

Germany
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN)

Diabetic Nephropathies

Hong Kong, Australia, Spain, Portugal, United States, France, Canada, Netherlands, Austria, Finland, Poland, Taiwan, Hungary, Israel, Italy, South Africa, Sweden, Bulgaria, Germany, Denmark, Czechia, Korea, Republic of, Norway
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)

Chronic Kidney Disease

Belgium, Finland, France, China, Hong Kong, Switzerland, United States, Turkey, Greece, New Zealand, Poland, South Africa, Spain, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, ... and more
Bayer

Completed

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR) (DeFineDR)

Diabetic Retinopathy

United Kingdom, Bulgaria
Bayer

Completed

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)

Diabetic Kidney Disease

Belgium, Finland, France, Spain, China, Hong Kong, Switzerland, United States, Colombia, Turkey, Greece, New Zealand, Poland, Korea, Republic of, Portugal, Taiwan, Japan, Russian Federation, Singapore, Australia, Netherlands, Sweden, Austr... and more
Bayer

Recruiting

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions (FINEROD)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Germany, Japan
Bayer

Active, not recruiting

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

Heart Failure

United States, Spain, Denmark, Korea, Republic of, Taiwan, Australia, Hong Kong, Russian Federation, Israel, Canada, Malaysia, United Kingdom, Latvia, Netherlands, Japan, Brazil, China, Lithuania, Poland, Turkey, Italy, Austria, Bul... and more
Bayer

Completed

A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution

Diabetic Nephropathy | Worsening Chronic Heart Failure

Germany
Bayer

Recruiting

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes (CONFIDENCE)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States, Belgium, Spain, Taiwan, Korea, Republic of, Netherlands, Japan, Italy, Denmark, Israel, Canada, France, India, Germany
Bayer

Completed

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Heart Failure

Germany
Bayer

Completed

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results (FLAMINGO)

Type 2 Diabetes | Chronic Kidney Disease

United States
Colorado Prevention Center
Bayer; Saint Luke's Hospital of Kansas City

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF)

Heart Failure | Acute Heart Failure

United States
Bayer

Active, not recruiting

An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions (FIRST-2)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States
Saga University

Active, not recruiting

Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) (FIVE-STAR)

Chronic Kidney Diseases | Type 2 Diabetes

Japan
Bayer

Completed

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Diabetic Nephropathies

Japan
The George Institute

Not yet recruiting

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE)

Chronic Kidney Diseases
University of North Carolina, Chapel Hill
Bayer

Recruiting

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

Kidney Transplant; Complications

United States
Chongqing Medical University

Recruiting

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

Primary Aldosteronism

China
Bayer

Completed

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone (ARTS-HF)

Heart Failure

France, Taiwan, United States, Turkey, Spain, Greece, Portugal, Germany, Canada, Austria, Czechia, Denmark, Israel, Korea, Republic of, Poland, South Africa, Sweden, Bulgaria, Italy, Finland, Hungary, Lithuania, Netherlands, Australia, ...
Bayer

Completed

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

Clinical Pharmacology

Germany
Bayer

Completed

BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease (ARTS)

Heart Failure

Denmark, Germany, Belgium, Austria, Czechia, Israel, Norway, Sweden, Poland, Finland
Bayer

Completed

Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone (ARTS-HF Japan)

Heart Failure

Japan
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
National Natural Science Foundation of China; National Key Research and Development...

Not yet recruiting

Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism

Hypertension | Primary Aldosteronism
Bayer

Active, not recruiting

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice (FINEGUST)

Type 2 Diabetes Mellitus | Chronic Kidney Disease

Japan, Spain, Netherlands, United Kingdom, Denmark, United States
University Medical Center Groningen
Boehringer Ingelheim

Not yet recruiting

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (Optimize@Home)

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Complications | Chronic Kidney Diseases | Albuminuria | CKD | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | CKD Stage 4 | CKD Stage 3 | Chronic Kidney Disease Due to Type 2 Diabetes Mellitus | Diabetes Mellitus Type 2 With Proteinuria

3

Subscribe